mRNA Synthesis Raw Materials Market To Reach $1.99 Billion By 2030

mRNA Synthesis Raw Materials Market Growth & Trends

The global mRNA synthesis raw materials market size is projected to reach USD 1.99 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 2.85% from 2024 to 2030. The major factors driving the market growth include growing academic and industrial interest in mRNA technology, the advantages of mRNA vaccines, and increasing funding for research. In addition, the increasing therapeutic applications of RNA technology are projected to offer lucrative opportunities for the mRNA synthesis raw materials market during the forecast period.

The COVID-19 pandemic has increased the demand for mRNA synthesis raw materials for developing an efficient vaccine to battle infectious diseases. mRNA vaccines are a safe and efficient method for preventing COVID-19. In addition, the advantages associated with the mRNA COVID-19 vaccines have sparked the attention of pharmaceutical businesses in delivering vaccines swiftly across the globe. For instance, the National Institute of Allergy and Infectious Diseases and Moderna, Inc. mutually developed the mRNA-1273 (NIAID) in March 2020. As a result, the usage of mRNA vaccines increased significantly during the COVID-19 pandemic.

Furthermore, many major pharmaceutical firms have started working on mRNA-based therapeutics, including Novartis, Alexion, AstraZeneca, Pfizer, Sanofi Pasteur, and Shire. For instance, in January 2022, according to a development and option agreement between Pfizer Inc. and Acuitas Therapeutics, Pfizer will have the option to license Acuitas' LNP technology for up to 10 targets for the development of mRNA therapeutics & vaccines. Therefore, the adoption rate of mRNA synthesis raw materials has increased among pharma & biotech companies, which further fuels the market growth.

Moreover, due to the temporary nature of mRNA translation and lack of integration of the foreign material into the cell's genome, the resulting cellular therapeutic product has a number of benefits over the one obtained by a more conventional approach. Some of the advantages include easier production under acceptable manufacturing procedures, reduced cytotoxicity from on-target off-tumor effects, and better clinical validation and regulatory treatment. Thus, such advantages are expected to increase the demand for mRNA therapeutics and further boost market growth.

Additionally, regarding the treatment and prevention of several diseases, mRNA-based technologies have been proven to be incredibly promising. Tremendous advances in technology and scientific study over the past ten years have made mRNA a feasible therapeutic option, eliminating some of the problems with its use, such as its brief half-life and innate immunogenicity. For instance, as mRNA technology advances, its fusion with new adoptive immunotherapies may result in safer and more efficient methods, such as the creation of cutting-edge chimeric antigen receptor T-cells. Therefore, advancements in mRNA technology are projected to open new avenues for market growth.

However, the high cost of raw materials may impede the market during the study period. For instance, the purchase price of raw materials, such as CleanCap AG, accounts for around 45% of the total raw material costs incurred while producing both vaccines. In addition, the regulatory framework pertaining to approval processes has always been the most critical restraining factor in the biotechnology, pharmaceutical, and medical technology industry. The absence of effective regulatory framework/guidelines for the therapeutic sector in developing countries such as China and India, where the mRNA synthesis raw materials market holds great growth potential due to the presence of a large patient base, is anticipated to impede the market growth in the coming years.

 Request a free sample copy or view report summary: mRNA Synthesis Raw Materials Market Report

mRNA Synthesis Raw Materials Market Report Highlights

• The capping agents segment held the largest share of 39.17% in 2023 owing to the advancements in the capping technology and their applications in the biopharma industry and research

• By application, The vaccine production segment dominated the global industry with the largest revenue share in 2023. This can be attributed to the rapid production of mRNA vaccines compared to the conventional vaccines that utilize cell-culture-based production paths, which are often prone to failure.

• North America dominated the global industry in 2023 and accounted for the largest share of more than 36.77% of the overall revenue in 2023, and is expected to grow at the highest CAGR over the forecast period.

• The biopharmaceutical and pharmaceutical companies segment dominated the market with the highest revenue share in 2023, due to the high commercial success of biopharmaceuticals and rapid growth in demand for therapeutics.

mRNA Synthesis Raw Materials Market Segmentation

Grand View Research has segmented the global mRNA synthesis raw materials market on the basis of type, application, end-use, and region:

mRNA Synthesis Raw Materials Type Outlook (Revenue, USD Million, 2018 - 2030)

• Capping Agents

• Nucleotides

• Plasmid DNA

• Enzymes

  • Others

  • DNase

  • RNase Inhibitor

  • Polymerase

• Others

mRNA Synthesis Raw Materials Application Outlook (Revenue, USD Million, 2018 - 2030)

• Vaccine Production

• Therapeutics Production

• Others

mRNA Synthesis Raw Materials End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Biopharmaceutical & Pharmaceutical Companies

• CROs & CMOs

• Academic & Research Institutes

mRNA Synthesis Raw Materials Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of mRNA Synthesis Raw Materials Market

• F. Hoffmann-La Roche Ltd.

• Jena Bioscience GmbH

• Merck KGaA

• Yeasen Biotechnology (Shanghai) Co., Ltd.

• BOC Sciences

• Thermo Fisher Scientific, Inc.

• Maravai LifeSciences

• New England Biolabs

• Creative Biogene

• HONGENE.